中危甲状腺癌患者治疗反应评估:是否需要促甲状腺激素刺激下的甲状腺球蛋白检测
本研究纳入120例中危分化型甲状腺癌患者,比较基于刺激后甲状腺球蛋白(Tg)的ATA治疗反应(RTT)评估与基于基础Tg、治疗后全身扫描(TxWBS)及结构影像的非刺激系统的预后价值。随访7±4年,两种系统预测价值无差异,曲线下面积分别为0.903和0.918。作者建议采用基于基础Tg联合TxWBS和结构影像的卓越反应评估。
要点
- 中危分化型甲状腺癌患者随访7±4年,26%存在持续性疾病(14%生化,12%结构)。
- 基于刺激Tg的ATA系统与基于基础Tg的非刺激系统预测价值无差异,AUC分别为0.903和0.918。
- 仅7%患者因重组人促甲状腺激素刺激而被重新分类,作者建议采用基于基础Tg联合TxWBS和结构影像的卓越反应评估。
核心结论
- 在随访前2年无疾病证据的患者中,加做刺激后Tg提供的预后信息很少。
- 作者建议采用基于基础Tg联合治疗后全身扫描和结构影像的卓越治疗反应评估。
研究设计与样本
- 回顾性队列研究,纳入120例接受全甲状腺切除和放射性碘治疗的中危分化型甲状腺癌患者,随访>2年且随访数据充分。
- 中危原因包括淋巴结受累(72%)、甲状腺外侵犯(51%)、血管侵犯(12%)和高危组织学(9%)。
主要发现
- 随访7±4年结束时,26%存在持续性疾病(14%生化,12%结构)。
- 按ATA治疗反应系统(使用刺激后Tg),56%为卓越反应,其中仅2%在随访结束时存在疾病。
- 按非刺激系统(包括基础Tg、术后治疗后全身扫描评估残留淋巴结转移及结构影像),57%为卓越反应,其中无人在随访结束时存在疾病。
- 仅8例(7%)因重组人促甲状腺激素刺激而被分类不同(卓越或不确定反应),预测价值无差异,受试者工作特征曲线下面积含Tg刺激为0.903,不含为0.918。
关键数值与推荐
- 2015年美国甲状腺协会(ATA)指南推荐在分化型甲状腺癌初始治疗后1-2年进行评估治疗反应,以指导促甲状腺激素(TSH)目标和长期随访。
临床怎么用
- 作者建议对随访前2年无疾病证据的中危分化型甲状腺癌患者,采用基于基础Tg联合治疗后全身扫描和结构影像的卓越治疗反应评估,不必加做刺激后Tg。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Introduction: The 2015 American Thyroid Association (ATA) guidelines recommend response to therapy (RTT) assessment 1-2 years after initial treatment in differentiated thyroid cancer (DTC) patients to guide thyrotropin (TSH) goals and long-term follow-up. We hypothesized that data collected during the first 2 years of follow-up may be sufficient to determine RTT without thyroglobulin (Tg) stimulation. Materials and Methods: Patients treated with total thyroidectomy and radioiodine for intermediate-risk DTC, followed for >2 years, and had sufficient follow-up data were included. Data on Tg, ultrasound, scans, and long-term outcomes were collected. Results: One-hundred twenty patients met inclusion criteria, with 68% women and mean age 55 ± 15 years. Intermediate risk was due to lymph-node involvement (72%), extrathyroidal extension (51%), vascular invasion (12%), and high-risk histology (9%). At the end of follow-up of 7 ± 4 years, 26% had persistent disease (14% biochemical, 12% structural). According to the ATA RTT system (using stimulated-Tg), 56% had excellent RTT, of whom only 2% had disease at the end of follow-up. In the "nonstimulated" system (which includes basal Tg, post-131I therapy whole-body scan (TxWBS) for assessment of residual lymph-node metastases after surgery, and structural imaging studies), 57% had excellent response, of whom none had disease at the end of follow-up. Only eight patients (7%) were classified differently due to recombinant human thyrotropin stimulation (as either excellent or indeterminate response), with no difference in predictive value, with a receiver-operator characteristic area under the curve of 0.903 with Tg-stimulation and of 0.918 without. Conclusions: In patients with no evidence of disease during the first 2 years of follow-up, the addition of stimulated-Tg adds little prognostic information. We suggest the use of excellent RTT based on basal Tg together with TxWBS and structural imaging studies.
引用
- Moreno I, Hirsch D, Duskin-Bitan H, et al. Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required? Thyroid. 2020. PMID: 31928205. doi:10.1089/thy.2019.0431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。